Kenneth Erland Johnson - Jan 29, 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Signature
/s/ Beth Hecht, as Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jan 29, 2022
Transactions value $
-$146,264
Form type
4
Date filed
8/9/2024, 04:07 PM
Previous filing
Jan 5, 2022
Next filing
Feb 1, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability -$15.8K -7.5K -1.67% $2.11* 440K Jan 29, 2022 Direct F1, F2, F3
transaction XERS Common Stock Tax liability -$4.87K -2.31K -0.52% $2.11* 438K Jan 31, 2022 Direct F1, F4
transaction XERS Common Stock Tax liability -$13.9K -12.4K -2.83% $1.12 426K Jan 3, 2023 Direct F1, F5
transaction XERS Common Stock Tax liability -$13.9K -11K -2.59% $1.26 415K Jan 29, 2023 Direct F1, F6
transaction XERS Common Stock Tax liability -$4.21K -3.39K -0.82% $1.24 411K Jan 31, 2023 Direct F1, F7
transaction XERS Common Stock Tax liability -$27.8K -12.4K -3.01% $2.24 399K Jan 3, 2024 Direct F1, F8
transaction XERS Common Stock Tax liability -$28.6K -10.7K -2.69% $2.66 388K Jan 29, 2024 Direct F1, F9
transaction XERS Common Stock Tax liability -$37.2K -15.1K -3.9% $2.46 373K Jan 31, 2024 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction is being reported late due to administrative oversight.
F2 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022.
F3 These shares include 1,080 shares that were purchased on June 30, 2024 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
F4 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
F5 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
F6 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
F7 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
F8 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
F9 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
F10 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.

Remarks:

Senior Vice President, Global Development and Medical Affairs